Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma

BACKGROUND: Medulloblastoma (MB) is the most common malignant paediatric brain tumour and a leading cause of cancer-related mortality and morbidity. Existing treatment protocols are aggressive in nature resulting in significant neurological, intellectual and physical disabilities for the children un...

Descripción completa

Detalles Bibliográficos
Autores principales: Genovesi, Laura A., Millar, Amanda, Tolson, Elissa, Singleton, Matthew, Hassall, Emily, Kojic, Marija, Brighi, Caterina, Girard, Emily, Andradas, Clara, Kuchibhotla, Mani, Bhuva, Dharmesh D., Endersby, Raelene, Gottardo, Nicholas G., Bernard, Anne, Adolphe, Christelle, Olson, James M., Taylor, Michael D., Davis, Melissa J., Wainwright, Brandon J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215804/
https://www.ncbi.nlm.nih.gov/pubmed/34154646
http://dx.doi.org/10.1186/s13073-021-00920-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215804/
https://www.ncbi.nlm.nih.gov/pubmed/34154646
http://dx.doi.org/10.1186/s13073-021-00920-z

Ejemplares similares